Clinical Trial Results:
An open-label study to evaluate the penetration of doripenem in cerebrospinal fluid after doripenem administration in pediatric subjects less than 1 year chronological age
Summary
|
|
EudraCT number |
2011-001114-33 |
Trial protocol |
BE PL |
Global end of trial date |
02 Jun 2012
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
09 Jun 2016
|
First version publication date |
24 Jul 2015
|
Other versions |
v1 |
Version creation reason |
|
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
DORIPED1002
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01366651 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Janssen-Cilag International NV
|
||
Sponsor organisation address |
Archimedsweg 29-2333CM, Leiden, Netherlands,
|
||
Public contact |
Clinical Registry Group, Janssen-Cilag International NV,Janssen Research & Development, ClinicalTrialsEU@its.jnj.com
|
||
Scientific contact |
Clinical Registry Group, Janssen-Cilag International NV,Janssen Research & Development, ClinicalTrialsEU@its.jnj.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
03 Oct 2013
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
02 Jun 2012
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
02 Jun 2012
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
The purpose of this study is to characterize the penetration of doripenem in the cerebral spinal fluid in pediatric participants less then (<1) year of age who are hospitalized and have a documented or suspected infection and are planning to, or undergoing treatment with intravenous (IV) antibiotics.
|
||
Protection of trial subjects |
Safety evaluation included following assessments: Physical examinations including body weigh ,Vital sign measurements included blood pressure, pulse rate, respiratory rate (and documentation if a participants was on a ventilator or not), and temperature (skin probe, rectal, axillary, or other) was examined.Vital signs were measured before the start of study drug infusion and within 15 minutes after the end of each doripenem infusion. Adverse events were reported throughout the study.This study was conducted in compliance with the protocol, Good Clinical Practice, and applicable regulatory requirements. A safety committee composed of the medical monitor, 1 of the study’s investigators, and 1 expert in paediatrics reviewed the safety while the study was on-going.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
27 May 2012
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Belgium: 1
|
||
Worldwide total number of subjects |
1
|
||
EEA total number of subjects |
1
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
1
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
- | ||||||
Pre-assignment
|
|||||||
Screening details |
One participant was enrolled into the study. | ||||||
Period 1
|
|||||||
Period 1 title |
Overall Study (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Non-randomised - controlled
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
Doripenem | ||||||
Arm description |
Doripenem was administered as intravenous infusion for 1 hour every 8 hours at a concentration of 10 milligram per milliliter (mg/ml). The doripenem dose was 10 milligram per kilogram (mg/kg) for participants less than 12 weeks and 30 mg/kg for participants 12 weeks to less than one year of age. | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Doripenem
|
||||||
Investigational medicinal product code |
JNJ-38174942
|
||||||
Other name |
|||||||
Pharmaceutical forms |
Powder and solution for solution for injection
|
||||||
Routes of administration |
Intravenous use
|
||||||
Dosage and administration details |
Doripenem was administered as intravenous infusion for 1 hour every 8 hours at a concentration of 10 milligram per milliliter (mg/ml). Total dose was 10 milligram per kilogram (mg/kg) for participants of less than 12 weeks and 30 mg/kg for participants of 12 weeks to less than one year.
|
||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Doripenem
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Doripenem was administered as intravenous infusion for 1 hour every 8 hours at a concentration of 10 milligram per milliliter (mg/ml). The doripenem dose was 10 milligram per kilogram (mg/kg) for participants less than 12 weeks and 30 mg/kg for participants 12 weeks to less than one year of age. | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Doripenem
|
||
Reporting group description |
Doripenem was administered as intravenous infusion for 1 hour every 8 hours at a concentration of 10 milligram per milliliter (mg/ml). The doripenem dose was 10 milligram per kilogram (mg/kg) for participants less than 12 weeks and 30 mg/kg for participants 12 weeks to less than one year of age. |
|
|||||||||
End point title |
Doripenem concentration in Cerebrospinal fluid [1] | ||||||||
End point description |
Doripenem concentration was analyzed by validated, specific and sensitive liquid-chromatography/tandem mass spectrometry (LC-MS/MS) method.
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
17 minutes after end of Doripenem one hour infusion
|
||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive statistics were done, no inferential statistical analyses were performed |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Doripenem concentration in Plasma [2] | ||||||||||||
End point description |
Doripenem concentration was analyzed by validated, specific and sensitive liquid-chromatography/tandem mass spectrometry (LC-MS/MS) method.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
10,29 minutes after end of Doripenem one hour infusion
|
||||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive statistics were done, no inferential statistical analyses were performed |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||
Adverse events information [1]
|
|||||||||||
Timeframe for reporting adverse events |
Up to Day 9.
|
||||||||||
Assessment type |
Systematic | ||||||||||
Dictionary used for adverse event reporting
|
|||||||||||
Dictionary name |
MedDRA | ||||||||||
Dictionary version |
15.0
|
||||||||||
Reporting groups
|
|||||||||||
Reporting group title |
Doripenem
|
||||||||||
Reporting group description |
Doripenem was administered as intravenous infusion for 1 hour every 8 hours at a concentration of 10 milligram per milliliter (mg/ml). Total dose was 10 milligram per kilogram (mg/kg) for participants of less than 12 weeks and 30 mg/kg for participants of 12 weeks to less than one year. | ||||||||||
|
|||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||
|
|||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: There are no non-serious AEs reported. |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
26 Oct 2011 |
This amendment is considered to be substantial. The overall reason for the amendment is to provide clarification on a number of items and to align the protocol with recommended from investigators. It includes that the Body weight was not be collected on the day of the first doripenem infusion (Day 1). To specify the age of participants to be enrolled in days. To clarify the vital signs to be collected in the footnote of the Time & Events Schedule. To clarify the amount of time allowed between the start of the doripenem administration and the End-of-Study assessment and that CSF samples must be obtained from only a LP or VP shunt tap and that CSF sampling by other methods is not allowed. To clarify that the exclusion criteria to provide examples of the types of blood components not permitted to be administered and when. To avoid disruption of the equilibrium between plasma doripenem concentrations and CSF doripenem concentrations on study days when both samples was collected. To clarify the acceptable timeframe for eCRFs must be completed. The Centrifugation of the CSF samples is requested to avoid potential contamination of CSF with doripenem from blood components. To reduce possible physiologic variability that may confound the interpretation of pharmacokinetic data and clarification that participants should not have received an investigational compound (rather than having participated in a clinical study) within 2 weeks of the first dose of doripenem in this study. To clarify that participants with hematocrit level <30% are excluded from study participation. The timing of drawing of blood samples to match the CSF sample was clarified to avoid misunderstanding of the instructions. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
The objectives of study could not be achieved as study was terminated early on 1-july-2013 for business reasons, and is not related to any safety issues or concerns. Only 1 participant was enrolled into the study. |